A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

NCT02254538 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BILR 355 BS
DRUG: PEG 400

Sponsor

Boehringer Ingelheim